SKAP2 and atherosclerosis: Essentially, these therapies exploit the fact that senescent cells exhibit a markedly enhanced SAPS activity, which, in atherosclerosis, modulates in an autocrine manner the activity of the senescent cell, as well as that of the cellular senescence process and associated damage in a paracrine and endocrine manner, related to epigenetic mechanisms.